Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREEDOM-Ev early add-on oral treprostinil trial in pulmonary arterial hypertension
MOH_2017-04-24_000337Phase 3Recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Sep 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Oral treprostinil plus background oral monotherapy with Placebo plus background oral monotherapy (2 arms). Primary endpoints: Time to first clinical worsening event and 6-minute walk distance at week 24. Started Sep 2012; status: recruiting.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2017-04-24_000337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-24_000337.